Synonym:
(5Z,7E,22E)-9,10-Secoergosta-5,7,10(19),22-tetraene-1α,3β-diol,
(5Z,7E,22E)-9,10-Secoergosta-5,7,10(19),22-tetraene-1,3-diol,
1α-Hydroxyergocalciferol,
1α-Hydroxyvitamin D2,
1α-OHD2,
1-α-Hydroxyvitamin D2,
1-Hydroxyergocalciferol,
TSA 840
Properties:
Related Categories |
Analytical Standards,
Analytical/Chromatography,
Pharmacopeia & Metrological Institutes Standards,
USP Standards,
USP Standards C - D
|
Description:
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including MSDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.
For further information and support please go to the website of the issuing Pharmacopoeia.
Other Notes
Sales restrictions may apply.
USP issued SDS can be found here.
Biochem/physiol Actions
Doxercalciferol is a Vitamin D2 analogue, a Vitamin D Receptor Activator (VDRA). Doxercalciferol acts as a pro-hormone, needing 25-hydroxylation in the liver for bioactivation into 1α, 25-hydroxyvitamin D2. Pivotal studies in adults on dialysis have demonstrated control of secondary hyperparathyroidism that is superior to placebo therapy, without undue suppression of 1st IMA-PTH < 300 pg/mL, or occurrences of hypercalcemia. Doxercalciferol has been shown to be effective in controlling secondary hyperparathyroidism of adult patients with CKD stages 3-4.
Doxercalciferol is a vitamin D2 analog that acts as a pro-hormone, activated in the liver to 1α,25-dihydroxyvitamin D2. Despite its relatively low affinity for the vitamin D receptor (VDR) (before activation), it is effective at suppressing expression of the parathyroid hormone (PTH) gene, and appears to act through the VDR.
Safety:
Symbol
GHS06
Precautionary statements
Missing Phrase - N15.00950417